Immunotherapy for Epstein-Barr virus-associated cancers in children

Oncologist

Volumn 8, Issue 1, 2003, Pages 83-98

  Straathof, Karin C M ^a   Bollard, Catherine M ^a   Rooney, Cliona M ^a   Heslop, Helen E ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Cytotoxic T cells; Epstein Barr virus; Immunotherapy; Lymphoproliferative disease; Transplantation

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; CD30 ANTIGEN; CYTOKINE; GANCICLOVIR; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 6; MONOCLONAL ANTIBODY; RITUXIMAB; VIRUS ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER INCIDENCE; CHILDHOOD CANCER; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HODGKIN DISEASE; IMMUNE RESPONSE; IMMUNOTHERAPY; LATENT VIRUS INFECTION; LYMPHOPROLIFERATIVE DISEASE; NASOPHARYNX CANCER; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR;

ANTIGENS, VIRAL; BURKITT LYMPHOMA; CHILD; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; IMMUNOTHERAPY; LYMPHOPROLIFERATIVE DISORDERS; NASOPHARYNGEAL NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0037283241     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-1-83     Document Type: Article

References (131)

1. Cohen JI. Epstein-Barr virus infection. N Engl J Med 2000;343:481-492.
2. Niedobitek G, Agathanggelou A, Herbst H et al. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol 1997;182:151-159.
3. Sixbey JW, Nedrud JG, Raab-Traub N et al. Epstein-Barr virus replication in oropharyngeal epithelial cells. N Engl J Med 1984;310:1225-1230.
4. Qu L, Rowe DT. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J Virol 1992;66:3715-3724.
5. Tierney RJ, Steven N, Young LS et al. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol 1994;68:7374-7385.
6. Hsu JL, Glaser SL. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 2000;34:27-53.
7. d'Amore ES, Manivel JC, Gajl-Peczalska KJ et al. B-cell lymphoproliferative disorders after bone marrow transplant. An analysis of ten cases with emphasis on Epstein-Barr virus detection by in situ hybridization. Cancer 1991;68:1285-1295.
8. Babcock GJ, Decker LL, Freeman RB et al. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J Exp Med 1999;190:567-576.
9. Rowe DT, Qu L, Reyes J et al. Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol 1997;35:1612-1615.
10. Niesters HG, van Esser J, Fries E et al. Development of a real-time quantitative assay for detection of Epstein-Barr virus. J Clin Microbiol 2000;38:712-715.
11. Wagner HJ, Wessel M, Jabs W et al. Patients at risk for development of post-transplant lymphoproliferative disorder: plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation 2001;72:1012-1019.
12. Nalesnik MA, Locker J, Jaffe R et al. Clonal characteristics of post-transplant lymphoproliferative disorders. Transplant Proc 1988;20:280-283.
13. Micallef IN, Chhanabhai M, Gascoyne RD et al. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience. Bone Marrow Transplant 1998;22:981-987.
14. Curtis RE, Travis LB, Rowlings PA et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208-2216.
15. Barker JN, Martin PL, Coad JE et al. Low incidence of Epstein-Barr virus-associated post-transplantation lymphoproliferative disorders in 272 unrelated-donor umbilical cord blood transplant recipients. Biol Blood Marrow Transplant 2001;7:395-399.
16. Gross TG, Steinbuch M, DeFor T et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999;23:251-258.
17. Bhatia S, Ramsay NK, Steinbuch M et al. Malignant neoplasms following bone marrow transplantation. Blood 1996;87:3633-3639.
18. Hale G, Waldmann H. Risks of developing Epsteih-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood 1998;91:3079-3083.
19. Cavazzana-Calvo M, Bensoussan D, Jabado N et al. Prevention of EBV-induced B-lymphoproliferative disorder by ex vivo marrow B-cell depletion in HLA-phenoidentical or non-identical T-depleted bone marrow transplantation. Br J Haematol 1998;103:543-551.
20. Fischer A, Blanche S, Le Bidois J et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991;324:1451-1456.
21. Benkerrou M, Jais JP, Leblond V et al. Anti-B-cell monoclonal antibody treatment of severe post-transplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998;92:3137-3147.
22. Kuehnle I, Huls MH, Liu Z et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000;95:1502-1505.
23. Skoda-Smith S, Douglas VK, Mehta P et al. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab. Bone Marrow Transplant 2001;27:329-332.
24. Faye A, Quartier P, Reguerre Y et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001;115:112-118.
25. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-1191.
26. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 1997;276:1719-1724.
27. Tiberghien P. Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation. J Intern Med 2001;249:369-377.
28. Thomis DC, Marktel S, Bonini C et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001;97:1249-1257.
29. Riddell SR, Elliot M, Lewinsohn DA et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 1996;2:216-223.
30. Sauce D, Bodinier M, Garin M et al. Retrovirus-mediated gene transfer in primary T lymphocytes impairs their anti-Epstein-Barr virus potential through both culture-dependent and selection process-dependent mechanisms. Blood 2002;99:1165-1173.
31. Rooney CM, Smith CA, Ng CY et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet 1995;345:9-13.
32. Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998;92:1549-1555.
33. Heslop HE, Ng CY, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med 1996;2:551-555.
34. Gustafsson A, Levitsky V, Zou JZ et al. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop post-transplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000;95:807-814.
35. Gottschalk S, Ng CY, Perez M et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001;97:835-843.
36. Chadburn A, Suciu-Foca N, Cesarman E et al. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995;147:1862-1870.
37. Ho M, Jaffe R, Miller G et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988;45:719-727.
38. Nalesnik MA. Clinicopathologic features of post-transplant lymphoproliferative disorders. Ann Transplant 1997;2:33-40.
39. Collins MH, Montone KT, Leahey AM et al. Post-transplant lymphoproliferative disease in children. Pediatr Transplant 2001;5:250-257.
40. Finn L, Reyes J, Bueno J et al. Epstein-Barr virus infections in children after transplantation of the small intestine. Am J Surg Pathol 1998;22:299-309.
41. Ho M. Risk factors and pathogenesis of post-transplant lymphoproliferative disorders. Transplant Proc 1995;27:38-40.
42. Suryanarayan K, Natkunam Y, Berry G et al. Modified cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone therapy for post-transplantation lymphoproliferative disease in pediatric patients undergoing solid organ transplantation. J Pediatr Hematol Oncol 2001;23:452-455.
43. Swinnen LJ, Mullen GM, Carr TJ et al. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995;86:3333-3340.
44. Gross TG, Hinrichs SH, Winner J et al. Treatment of post-transplant lymphoproliferative disease (PTLD) following solid organ transplantation with low-dose chemotherapy. Ann Oncol 1998;9:339-340.
45. Darenkov IA, Marcarelli MA, Basadonna GP et al. Reduced incidence of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder using preemptive antiviral therapy. Transplantation 1997;64:848-852.
46. Muller CA, Walz J, Zinser R et al. In vivo induction of HLA molecules in patients with myeloproliferative syndrome during IFN alpha treatment. Ann Hematol 1991;63:259-263.
47. Salazar-Mather TP, Ishikawa R, Biron CA. NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection. J Immunol 1996;157:3054-3064.
48. Davis CL, Wood BL, Sabath DE et al. Interferon-alpha treatment of post-transplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998;66:1770-1779.
49. Davis CL. Interferon and cytotoxic chemotherapy for the treatment of post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001;3:108-118.
50. Haddad E, Paczesny S, Leblond V et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001;97:1590-1597.
51. Leblond V, Sutton L, Dorent R et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995;13:961-968.
52. Cook RC, Connors JM, Gascoyne RD et al. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation [letter]. Lancet 1999;354:1698-1699.
53. McGhee W, Mazariegos GV, Sindhi R et al. Rituximab in the treatment of pediatric small bowel transplant patients with post-transplant lymphoproliferative disorder unresponsive to standard treatment. Transplant Proc 2002;34:955-956.
54. Serinet MO, Jacquemin E, Habes D et al. Anti-CD20 monoclonal antibody (rituximab) treatment for Epstein-Barr virus-associated, B-cell lymphoproliferative disease in pediatric liver transplant recipients. J Pediatr Gastroenterol Nutr 2002;34:389-393.
55. Haque T, Taylor C, Wilkie GM et al. Complete regression of post-transplant lymphoproliferative disease using partially HLA-matched Epstein-Barr virus-specific cytotoxic T cells. Transplantation 2001;72:1399-1402.
56. Khanna R, Bell S, Sherritt M et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with post-transplant lymphoproliferative disease. Proc Natl Acad Sci USA 1999;96:10391-10396.
57. Savoldo B, Goss J, Liu Z et al. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 2001;72:1078-1086.
58. Comoli P, Labirio M, Basso S et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood 2002;99:2592-2598.
59. + cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals. Transplantation 2000;70:1507-1515.
60. + cytotoxic T cells from virus naive individuals. J Immunol 2002;168:909-918.
61. Emanuel DJ, Lucas KG, Mallory Jr. GB et al. Treatment of post-transplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes. Transplantation 1997;63:1691-1694.
62. Haque T, Wilkie G, Taylor C et al. Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002;360:436-442.
63. Gu SY, Huang TM, Ruan L et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995;84:171-177.
64. Herr W, Ranieri E, Olson W et al. Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4(+) and CD8(+) T lymphocyte responses. Blood 2000;96:1857-1864.
65. Suzan F, Ammor M, Ribrag V. Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 2001;345:1000.
66. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-615.
67. Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 2000;11:374-375.
68. Harjunpaa A, Wiklund T, Collan J et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001;42:731-738.
69. Rooney CM, Loftin SK, Holladay MS et al. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995;89:98-103.
70. Lucas KG, Burton RL, Zimmerman SE et al. Semiquantitative Epstein-Barr virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998;91:3654-3661.
71. Hoshino Y, Kimura H, Kuzushima K et al. Early intervention in post-transplant lymphoproliferative disorders based on Epstein-Barr viral load. Bone Marrow Transplant 2000;26:199-201.
72. Lankester AC, van Tol MJ, Vossen JM et al. Epstein-Barr virus (EBV)-DNA quantification in pediatric allogenic stem cell recipients: prediction of EBV-associated lymphoproliferative disease. Blood 2002;99:2630-2631.
73. van Esser JW, van der Holt B, Meijer E et al. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001;98:972-978.
74. Gridelli B, Spada M, Riva S et al. Circulating Epstein-Barr virus DNA to monitor lymphoproliferative disease following pediatric liver transplantation. Transpl Int 2000;13(suppl 1):S399-S401.
75. Green M, Bueno J, Rowe D et al. Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children. Transplantation 2000;70:593-596.
76. van Esser JW, Niesters HG, van der Holt B et al. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation. Blood 2002;99:4364-4369.
77. van Esser JW, Niesters HG, Thijsen SF et al. Molecular quantification of viral load in plasma allows for fast and accurate prediction of response to therapy of Epstein-Barr virus-associated lymphoproliferative disease after allogeneic stem cell transplantation. Br J Haematol 2001;113:814-821.
78. Yang J, Tao Q, Flinn IW et al. Characterization of Epstein-Barr virus-infected B cells in patients with post-transplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood 2000;96:4055-4063.
79. Kuzushima K, Kimura H, Hoshino Y et al. Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during post-transplant lymphoproliferative disorder. J Infect Dis 2000;182:937-940.
80. Yang J, Lemas VM, Flinn IW et al. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood 2000;95:241-248.
81. Gurney JG, Severson RK, Davis S et al. Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type. Cancer 1995;75:2186-2195.
82. Glaser SL, Lin RJ, Stewart SL et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer 1997;70:375-382.
83. Pallesen G, Sandvej K, Hamilton-Dutoit SJ et al. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells. Blood 1991;78:1162-1165.
84. Diehl V, Sextro M, Franklin J et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999;17:776-783.
85. Link MP, Shuster JJ, Donaldson SS et al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997;337:1259-1266.
86. Oberlin O, Leverger G, Pacquement H et al. Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol 1992;10:1602-1608.
87. Schellong G, Potter R, Bramswig J et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
88. Laurence AD, Goldstone AH. High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma. Semin Hematol 1999;36:303-312.
89. Beaty O, Hudson MM, Greenwald C et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol 1995;13:603-609.
90. Bhatia S, Robison LL, Oberlin O et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-751.
91. Aisenberg AC. Problems in Hodgkin's disease management. Blood 1999;93:761-779.
92. Stein H, Schwarting R, Dallenbach F et al. Immunology of Hodgkin and Reed-Sternberg cells. Recent Results Cancer Res 1989;117:14-26.
93. Engert A, Diehl V, Schnell R et al. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma. Blood 1997;89:403-410.
94. Barth S, Huhn M, Matthey B et al. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood 2000;95:3909-3914.
95. + Hodgkin's and non-Hodgkin's lymphoma. Clin Cancer Res 2002;8:1779-1786.
96. Hartmann F, Renner C, Jung W et al. Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 2001;7:1873-1881.
97. Roskrow MA, Suzuki N, Gan YJ et al. EBV-specific cytotoxic T lymphocytes for the treatment of patients with EBV positive relapsed Hodgkin's disease. Blood 1998;91:2925-2934.
98. + Hodgkin disease. Blood 2000;96:576a.
99. Newcom SR, Gu L. Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. J Clin Pathol 1995;48:160-163.
100. Poppema S, Potters M, Visser L et al. Immune escape mechanisms in Hodgkin's disease. Ann Oncol 1998;9(suppl 5):S21-S24.
101. Skinnider BF, Elia AJ, Gascoyne RD et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001;97:250-255.
102. van den BA, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltration Hodgkin's lymphoma. Am J Pathol 1999;154:1685-1691.
103. Gahn B, Siller-Lopez F, Pirooz AD et al. Enhanced immune response to the Epstein-Barr virus (EBV) antigen LMP2a using recombinant adenovirus transduced dendritic cells: a potential strategy for EBV-positive Hodgkin's lymphoma. Blood 2000;96(suppl 1):829a.
104. Su Z, Peluso MV, Raffegerst SH et al. The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease. Eur J Immunol 2001;31:947-958.
105. Dukers DF, Jaspars LH, Vos W et al. Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin's disease. J Pathol 2000;190:143-149.
106. Poppema S, Potters M, Visser L et al. Immune escape mechanisms in Hodgkin's disease. Ann Oncol 1998;9(suppl 5):S21-S24.
107. Scarpa S, Coppa A, Ragano-Caracciolo M et al. Transforming growth factor beta regulates differentiation and proliferation of human neuroblastoma. Exp Cell Res 1996;229:147-154.
108. Bollard CM, Rossig C, Calonge MJ et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood 2002;99:3179-3187.
109. Niedobitek G. Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma. Mol Pathol 2000;53:248-254.
110. Parkin DM. Epstein-Barr virus. Monograph IARC. 1997;70:47.
111. Pao WJ, Hustu HO, Douglass EC et al. Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. Int J Radiat Oncol Biol Phys 1989;17:299-305.
112. Wang CC, Chen ML, Hsu KH et al. Second malignant tumors in patients with nasopharyngeal carcinoma and their association with Epstein-Barr virus. Int J Cancer 2000;87:228-231.
113. Chua D, Huang J, Zheng B et al. Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int J Cancer 2001;94:73-80.
114. Shad A, Magrath I. Malignant non-Hodgkin's lymphomas in children. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, 3rd edition. Philadelphia, PA: Lippincott-Raven, 1997:545-587.
115. Rowe M, Gregory C. Epstein-Barr virus and Burkitt's lymphoma. Adv Viral Oncol 1989;8:237-259.
116. Levitskaya J, Coram M, Levitsky V et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 1995;375:685-688.
117. Leen A, Meij P, Redchenko I et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol 2001;75:8649-8659.
118. Munz C, Bickham KL, Subklewe M et al. Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med 2000;191:1649-1660.
119. Goedert JJ. The epidemiology of acquired immunodeficiency syndrome malignancies. Semin Oncol 2000;27:390-401.
120. Mueller BU. Cancers in children infected with the human immunodeficiency virus. The Oncologist 1999;4:309-317.
121. Hamilton-Dutoit SJ, Pallesen G. A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas. Am J Pathol 1992;140:1315-1325.
122. Hamilton-Dutoit SJ, Pallesen G, Franzmann MB et al. AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization. Am J Pathol 1991;138:149-163.
123. Cingolani A, Gastaldi R, Fassone L et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol 2000;18:3325-3330.
124. van Baarle D, Hovenkamp E, Callan MF et al. Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood 2001;98:146-155.
125. Kostense S, Otto SA, Knol GJ et al. Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells. Eur J Immunol 2002;32:1080-1089.
126. Fong IW, Ho J, Toy C et al. Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies. Clin Infect Dis 2000;30:757-761.
127. Raez L, Cabral L, Cai JP et al. Treatment of AIDS-related primary central nervous system lymphoma with zidovudine, ganciclovir, and interleukin 2. AIDS Res Hum Retroviruses 1999;15:713-719.
128. Brockmeyer NH, Pohl G, Mertins L. Combination of chemotherapy and antiviral therapy for Epstein-Barr virus-associated non-Hodgkin's lymphoma of high grade malignancy in cases of HIV infection. Eur J Med Res 1997;2:133-135.
129. Slobod KS, Taylor GH, Sandlund JT et al. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 2000;356:1493-1494.
130. Dharnidharka VR, Sullivan EK, Stablein DM et al. Risk factors for post-transplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001;71:1065-1068.
131. Swinnen LJ, Costanzo-Nordin MR; Fisher SG et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990;323:1723-1728.